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Abstract
A key goal of computational personalized medicine is to systemat-
ically utilize genomic and other molecular features of samples to pre-
dict drug responses for a previously unseen sample. Such predictions
are valuable for developing hypotheses for selecting therapies tailored
for individual patients. This is especially valuable in oncology, where
molecular and genetic heterogeneity of the cells has a major impact
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on the response. However, the prediction task is extremely challeng-
ing, raising the need for methods that can effectively model and pre-
dict drug responses. In this study, we propose a novel formulation of
multi-task matrix factorization that allows selective data integration
for predicting drug responses. To solve the modeling task, we extend
the state-of-the-art kernelized Bayesian matrix factorization (KBMF)
method with component-wise multiple kernel learning. In addition,
our approach exploits the known pathway information in a novel and
biologically meaningful fashion to learn the drug response associations.
Our method quantitatively outperforms the state of the art on predict-
ing drug responses in two publicly available cancer data sets as well
as on a synthetic data set. In addition, we validated our model pre-
dictions with lab experiments using an in-house cancer cell line panel.
We finally show the practical applicability of the proposed method by
utilizing prior knowledge to infer pathway-drug response associations,
opening up the opportunity for elucidating drug action mechanisms.
We demonstrate that pathway-response associations can be learned by
the proposed model for the well known EGFR and MEK inhibitors.
1 Introduction
The fundamental aim of personalized medicine is to design and identify indi-
vidualized therapies that maximize drug efficacy while minimizing the unde-
sirable side effects. The efficacy, however, depends on a multitude of factors,
including molecular, genetic, environmental and clinical characteristics of the
samples, and much of this information remains unknown. A promising re-
search direction is to computationally learn to predict, based on the available
molecular and genetic descriptions of the samples, the responses they elicit
in lab when exposed to a spectrum of drugs. The learned predictors help
identifying potential drug response associations, and can predict responses
for a new sample.
The development of molecular and genetic models of drug response has
been made possible through several recent large scale high-throughput screen-
ing efforts that profile large panels of human cancer cell lines and drugs (Bar-
retina et al., 2012; Garnett et al., 2012; Basu et al., 2013). Such models open
up the opportunity to study the impact of molecular characteristics on the
response, increasing our understanding of cancer vulnerabilities as well as
making it possible to build predictive models of drug responsiveness.
Recent advances have demonstrated that molecular and genomic features
have been useful in predicting the drug responses in cell lines (Costello et al.,
2014; Jang et al., 2014). However, a key challenge underlying predictive mod-
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eling is the small sample size and very large number of genomic features. The
small sample sizes offer limited statistical power leading to high uncertainty
in the predictions. The inherent heterogeneity across and within different
cancer types makes robust inference even harder. In the absence of technical
and practical facilities to overcome these limitations, a prospective direction
is to incorporate additional prior knowledge in a biologically meaningful way
to facilitate the learning process.
From the computational perspective, several methodologies have been
used to predict drug response (a detailed discussion in Section 2). A key
constituent of inferring the molecular and genetic model is the ability to effec-
tively integrate multiple side-data views (also called as side-data sources) for
prediction of the drug responses. Methods commonly referred to as multiple
kernel learning MKL (Gönen and Alpaydın, 2011) can extract the common
signal from multiple side-data views, effectively yielding an increased signal-
to-noise ratio in the parameter space and are currently the state of the art in
drug response prediction (Costello et al., 2014). Multi-task learning makes
it possible to learn a predictive model for all of the drugs jointly (multi-
task) making it possible to gather statistical evidence across multiple drugs
(Baxter, 2000).
In this study we introduce component-wise multiple kernel learning (MKL)
into the recent kernelized Bayesian matrix factorization (KBMF) method (Gö-
nen et al., 2013). The proposed model solves the prediction task by gathering
evidence from multiple side-data views, selectively, for each of the output
variable group. This formulation is particularly useful in drug response pre-
diction, for taking into account multiple side-data views. It need not assume
the same views to be relevant to all drugs as earlier methods, but instead
predictions can be based on different views for different groups of drugs.
The multiple side-data views can be generated based on the prior biolog-
ical knowledge; in the paper we use the pathways that are linked to the
known primary targets of the drugs. By systematically utilizing this type of
prior knowledge through kernelized Bayesian matrix factorization with the
component-wise MKL approach, we hypothesize that pathway-drug response
associations can be learned which are more informative for response predic-
tion, and additionally are better interpretable for understanding drug action
mechanisms.
Contributions
In this paper, we present a novel approach for improving accuracy of pre-
dicting drug responses and elucidating the underlying pathway-drug response
associations. Specifically, our contributions are two-fold:
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1. Methodologically we extend the current state-of-the-art model kernel-
ized Bayesian matrix factorization (KBMF) with component-wise mul-
tiple kernel learning (MKL). The extension can be seen as multi-task
learning by task factorization, however with selective data integra-
tion. Here the key assumption is that component-wise MKL allows
the method to better use prior biological knowledge (pathways) input
as multiple side-data views.
2. We introduce a way for incorporating prior biological knowledge, in the
form of pathways, for modeling pathway-drug response associations.
Instead of using a single side-data view for the genomic features, we
present pathway-based groups of features as multiple side-data views.
Here the key assumption is that informed grouping of the features intro-
duces additional structure and knowledge that is valuable for prediction
of particular drug groups.
We first demonstrate the model’s predictive abilities on a synthetic data set.
We then substantiate the significantly better performance of our approach
on predicting drug responses in two large publicly available cancer data sets.
In addition, we validate the in silico predictions of our model with lab ex-
periments on an in-house Acute Myeloid Leukemia (AML) cell line panel.
Finally, we examine the inferred associations between drug responses and
pathways in the larger data set, demonstrating a mechanism for elucidating
drug action mechanisms.
2 Related Work in drug response prediction
The computational task underlying personalized medicine is to predict drug
responses on new cancer cell lines, given a set of cancer cell lines for which
some measurements of drug responses are observed.
A common approach is to use the mean of the observed responses as pre-
dictions for the unobserved (unseen) drug responses (used as baseline method
here). Another well-known supervised approach uses the genomic and molec-
ular features of the cell lines (as input side-data) and the observed drug re-
sponses to learn a predictive model of the drug responses (Jang et al., 2014).
The available molecular and genomic features range from gene expression to
copy number and point mutations for the cancer cell lines, respectively (Bar-
retina et al., 2012; Garnett et al., 2012).
Another widely used approach is the quantitative structure-activity re-
lationship (QSAR) analysis which uses chemical and structural properties
(often called as descriptors) of the drugs and the observed responses to learn
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a predictive model to infer the unobserved responses. The descriptors vary
from 2D fingerprints to spatial characteristics and physiochemical features
of the drugs (Perkins et al., 2003; Myint and Xie, 2010; Shao et al., 2013).
Recently, an advanced approach has been proposed that learns a joint pre-
dictive model of the observed drug responses by combining both the genomic
features of the cell lines and descriptors of the drugs (Menden et al., 2013;
Ammad-ud din et al., 2014; Cortés-Ciriano et al., 2015; Zhang et al., 2015;
Cichonska et al., 2015).
Previous studies have used linear as well as non-linear methods. Lin-
ear methods including multivariate linear regression, partial least squares
(PLS) and principal component regression (PCR) are the most prominent.
Sparse linear regression has been well studied for identifying potential fea-
tures predictive of drug responses by enforcing elastic net regularization tech-
niques (Garnett et al., 2012; Barretina et al., 2012; Chen et al., 2015).
Nonlinear drug response analysis including kernel method, neural net-
works and random forests have also been studied (Sutherland et al., 2004;
Yamanishi et al., 2012; Menden et al., 2013; Cortés-Ciriano et al., 2015; Zhang
et al., 2015; Cichonska et al., 2015).
In particular, Costello et al. (2014) proposed Bayesian multi-task multiple
kernel learning (BMTMKL) to predict drug responses on new human breast
cancer cell lines. The BMTMKL method uses a kernelized regression ap-
proach that combines multi-task and multi-view learning (i.e., learning from
multiple side-data views) with Bayesian inference to estimate the model pa-
rameters. Their results showed that modeling nonlinearities in the data was
an essential attribute to predict drug responses. However, the model makes
the simplifying assumption that the predictions are based on a single under-
lying component.
Alternatively, matrix factorization models integrating side-data views
have also been studied in drug response analysis. The main idea behind
these methods is to jointly factorize the side-data views and output matrix
to finding a better low-dimensional latent representation (components) for
both rows and columns of the output matrix. To this end, Zhou et al. (2012)
proposed kernelized probabilistic matrix factorization (KPMF), a low-rank
matrix factorization method that uses Gaussian process priors with covari-
ance matrix on side-data view. While the method can explain tasks with
multiple components, it is, however, limited to a single kernel for each side
and, therefore, is unable to learn from multiple side-data views.
Recently, a kernelized Bayesian matrix factorization (KBMF) extending
kernelized matrix factorization with fully Bayesian inference, combining mul-
tiple side-data views to jointly factorize the output matrix has been pro-
posed (Gönen et al., 2013; Gönen and Kaski, 2014). With side-data views
5
encoded as kernel functions, the main idea is to project each kernel onto a
low-dimensional component space, where they are combined with the ker-
nel weights to get a composite component space of the output matrix. The
KBMF method has been studied in various applications ranging from drug-
target to drug response predictions (Gönen, 2012; Ammad-ud din et al.,
2014). However, KBMF integrates multiple side-data views assuming that a
source is either relevant for all tasks or none, failing to identify component-
specific dependencies between the side-data views and the output matrix.
3 Methods
Kernelized Bayesian Matrix Factorization (cwKBMF)
We introduce a novel extension of the state-of-the-art kernelized Bayesian
matrix factorization method to model the complex associations between a
large number of side-data views and the latent component space of the out-
put matrix. This new formulation of kernelized Bayesian matrix factorization
(KBMF) allows component-wise multiple kernel learning (MKL), referred to
as cwKBMF for brevity. cwKBMF is characterized by the ability to compre-
hensively model the associations that allow two advancements: i) improve
the predictive power of the model; and ii) identify the component-specific
latent dependencies for interpreting the associations.
The model is defined for the factorization of a given matrix Y ∈ RNx×Nz ,
using known sets of Px side-data views for the rows and Pz side-data views
for the columns. In order to represent non-linear associations, similarities
between samples in the side-data views are encoded as input kernel matrices
{Kx,m ∈ RNx×Nx}Pxm=1 and {Kz,n ∈ RNz×Nz}Pzn=1. Here matrices are denoted
by capital letters, with the subscript (x or z) indicating the corresponding
side of the model. All equations are formulated, however, with corresponding
scaler entities denoted by non-capital letters, with the superscript denoting
the row index and the last subscript representing the column index (i.e., aix,s
denotes the entry at (row i, column s) of matrix Ax). Without compromising
the generalizability, the rest of this article focuses on multiple side-data views
in the rows only.
The model is specified as a low-rank factorization of the matrix Y such
that the latent representations Hx ∈ RNx×R and Hz ∈ RNz×R are learned
jointly from Y and the Kx,m, Kz,m side-data views. This is achieved by an
interplay of two elements. First, each of the {Kx,m}Pxm=1 kernels is transformed
to a lower dimensional sub-space {Gx,m ∈ RNx×R}Pxm=1 through a common
projection matrix Ax ∈ RNx×R. The low-rank transformations of the kernels
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are combined using multiple kernel learning to compute the latent matrix
factors Hx.
The cwKBMF method is formulated in a Bayesian setting using conjugate
priors, where N (·;µ,Σ) denotes the normal distribution with mean µ and
covariance Σ, while G(·;α, β) is the gamma distribution with the parameters,
shape α and scale β. The matrix factorization is formulated as
yij|hx,i, hz,j ∼ N (yij;h>x,ihz,j, σ2y) ∀(i, j)
where i = 1 : Nx and j = 1 : Nz denote the samples and σy the noise.
Here hx,i and hz,j are vectors of length R, the number of components, and
represent the low-dimensional factors of the samples in Y .
Our extension formulates this factorization with the novel component-
wise MKL and has the distributional assumptions:
ηsx,m ∼ G(ηsx,m;αη, βη) ∀(m, s)
esx,m|ηsx,m ∼ N (esx,m; 0, (ηsx,m)−1) ∀(m, s)
hsx,i|{esx,m, gsx,m,i}Pxm=1 ∼ N
(
hsx,i;
Px∑
m=1
esx,mg
s
x,m,i, σ
2
h
)
∀(s, i)
where superscript s = 1 : R denotes the components. The novel advance-
ment of this formulation is in learning the latent components Hx as a com-
bination of kernel-specific components {Gx,m ∈ RNx×R}Pxm=1 while segregat-
ing between kernels that are component-specific and those which are shared
across all components. This is achieved by introducing component-specific
kernel weights esx,m ∈ RPx×R that control the activity of each kernel in each
component. This extension makes it possible for the method to effectively
learn the underlying structure for identifying the associations between ker-
nels and components. The method can also be viewed as combination of
component-wise multiple kernel learning and matrix factorization. The ηsx,m
defines an element-wise prior for the kernel-weights esx,m, making it possible
to effectively switch off some of the weights in a component-wise fashion.
Finally, the dimensionality reduction of the model has the distributional
assumptions:
λix,s ∼ G(λix,s;αλ, βλ) ∀(i, s)
aix,s|λix,s ∼ N (aix,s; 0, (λix,s)−1) ∀(i, s)
gsx,m,i|ax,s, kx,m,i ∼ N (gsx,m,i; a>x,skx,m,i, σ2g) ∀(m, s, i)
where a joint Ax matrix projects each of the kernels to a low-dimensional
representation. The hyper-parameters αλ, βλ, αη, βη, σg, σh, σy can be used
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to express prior knowledge about the data-generating process, or set to un-
informative values (as in this paper).
The model is formulated with conjugate priors and variational approxi-
mation is used to perform model inference. The computation-al complexity
of the model is O(Rmax(N3x , N3z ) + Rmax(P 3x , P 3z )) which is faster than
standard pair-wise kernel approaches (Ben-Hur and Noble, 2005) and slower
only linearly with a factor of R in max(P 3x , P 3z ), in comparison to original
KBMF formulation. The model achieves a run time to the tune of minutes
for reasonably sized data sets (≈ 5 minutes of wall clock time on a standard
computer, for a single cross validation fold on the largest data studied in this
manuscript).
Publicly Available Data sets and Preprocessing
We used two publicly available cancer data sets to model drug response
associations in this study.
Genomics of Drug Sensitivity in Cancer: The first data come from Ge-
nomics of Drug Sensitivity in Cancer (GDSC) project initiated by Wellcome
Trust Sanger Institute version release, June 2014 (Yang et al., 2013). The
data comprised of 124 human cancer cell lines and 124 anti-cancer drugs, for
which complete drug response measurements are available and the response
range is consistent with earlier publications (Garnett et al., 2012; Menden
et al., 2013). Drug response measurements are summarized as log IC50 val-
ues (micro molar concentration of a drug required to inhibit 50% of the cell
growth) obtained by curve fitting through the 9-point dose response data.
The cell lines are annotated with tissue type, and drugs with their primary
therapeutic targets.
Cancer Therapeutic Response Portal: The second data originate from
Cancer Theraupetic Response Portal (CTRP) version release v1 2013, (Basu
et al., 2013) by Broad Institute summarizing area-under-concentration-response
curve (AUC) values from 8-point dose response data measured on human
cancer cell lines. For our case study, we focus on the set of 66 cell lines and
63 anti-cancer drugs, whose AUC values were observed without missing val-
ues. The molecular profiles for the cell lines was obtained from Cancer Cell
line Encylopedia CCLE (Barretina et al., 2012). As in GDSC, the cell lines
are annotated with tissue type and gene expression, while drugs with their
primary therapeutic targets.
As the input data, we used the baseline gene expression values of all the
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cell lines quantizing the number of transcripts expressed in a cell. These
measurements characterize the genome-wide molecular profiles that may be
indicative of the response patterns.
Prior Biological Knowledge: In order to incorporate prior biological
knowledge, we used a selected set of pathways and gene sets from Molecu-
lar Signature database MSigDB (Liberzon et al., 2011). Specifically, we ex-
tracted the C2CP and C6 collections of pathways and genesets from MSigDB,
respectively. C2CP contains pathways compiled from online pathway databases,
biomedical literature, published mammalian gene expression studies and MYC
target gene database. C6 gene sets denote oncogene signatures of cellular
pathways which are often dis-regulated in cancer. These oncogene signatures
are computed using microarray data from NCBI GEO and from profiling
experiments involving perturbation of known cancer genes. For simplicity
in the rest of the paper, we use a common term for both of the collections:
pathways.
Experimental Setup
Incorporating Prior Biological Knowledge: We focused the analyses
on drug targets by, for each of the two collections, carefully selecting the
subset of pathways that were directly linked to the known primary targets of
the drugs. This was done by examining the correspondence between pathway
names and the known primary targets of the drugs. The drug target data
coming from the original annotations of GDSC and CTRP was used for this
purpose. The gene expression data were then split into groups of genes, where
each group represented one pathway. All the other genes which were not part
of any of the target-based pathway selection, were collected in a separate
single group (collectively called as “other genes”). When the variable groups
in the data are constructed in this way, the component-wise MKL based
data integration can choose what prior knowledge is useful for predicting
responses. Still, no knowledge is lost as all variables have been included,
and additionally allows to learn associations between other genes and the
responses. The total number of groups formed per case study are listed in
Table 1. We term each group with a keyword ‘view’.
Table 1: Data used in the drug response predictions.
Datasets Cells Drugs Genes Primary Targets Views
GDSC 124 124 13321 60 72 (71 pathways, 1 other genes)
CTRP 66 63 18988 58 26 (25 pathways, 1 other genes)
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Additional information about the data including the names of the cell
lines, drugs, primary targets and pathways can be found from the supple-
mentary material. The response data consist of both types of drugs: FDA
approved ‘drugs’ and ‘investigational chemical compounds’. In the paper, we
use both of these terms interchangeably.
Cross-Validation: We compared the performance of cwKBMF with sev-
eral methods including KBMFmulti-view; kernelized Bayesian matrix factor-
ization with pathway based groups, BMTMKLmulti-view; Bayesian multi-task
learning with pathway based groups, KPMFsingle-view; kernelized probabilistic
matrix factorization without pathway based groups, MT-LRsingle-view; multi-
task sparse linear regression without pathway based groups and the classical
Baseline; mean of the training drug response data (assuming no genomic
data is available).
We performed a 5-fold cross validation procedure, where in each fold
a randomly selected subset of cell lines is completely held-out (as test cell
lines) and models were trained on the remaining cell lines (training data). To
establish robust findings the 5-fold cross validation procedure was repeated
10 times with different random cross-validation folds.
For the kernelized Bayeisan methods (BMTMKL, KBMF and cwKBMF),
we use uninformative priors for the projection matrices and the kernel weights.
In particular, the hyperparameter values for BMTMKL are selected as (αλ,
βλ,αυ, βυ, αγ, βγ, αω, βω, α, β) = (1, 1, 1, 1, 1, 1, 1, 1, 1, 1) and for KBMF,
cwKBMF are selected as (αη, βη, αλ, βλ) = (1, 1, 1, 1), and the standard
deviations (σg, σh, σy) are set to (0.1, 0.1,1). For KPMF, the standard devia-
tion σy is set to one. For the side-data views, we computed Gaussian kernels,
where the width parameter σ was set in the standard way (σ = dimensional-
ity of the side-data view). The drug response measurements were normalized
to have zero mean and unit variance.
We used multi-task sparse linear regression using the glmnet package (Fried-
man et al., 2010). The sparse linear regression has two parameters that are
to be optimized: α (elastic net mixing parameter) and λ (the penalty param-
eter). For each test set prediction, we performed a nested 5-fold cross vali-
dation procedure on the training data, to choose optimal values for α ∈ [0, 1]
with an increment of 0.1 and λ (from 100 values). We finally selected a
combination of α and λ values that gave minimum error averaged over the
cross-validated folds.
Evaluation Criteria: We evaluated the predictive performance of cwKBMF
and other methods using drug-wise spearman correlation as an evaluation
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criterion and report an averaged correlation for each drug from 10 random
repeats of the cross-validation procedure. In addition, the correlations were
averaged to obtain a cumulative correlation value for each method.
4 Results and Discussion
Synthetic Data Set
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Figure 1: Identification of component-view activities and predictions on syn-
thetic data set. Method abbreviation: cwKBMF, kernelized Bayesian matrix
factorization with component-wise MKL; KBMF, kernelized Bayesian matrix
factorization. Left: The component-view activities learned by the model.
Black indicates that a view is active in a component while white represents
not-active. Middle: the mean squared error (MSE) of predictions, averaged
over 100 data sets at each point (and bars denoting 1-standard error of the
mean (1SE)). The performance is indicative of the models ability to discover
the underlying structure of the data. Right: The accuracy of the model to
discover component-view associations. The true and the inferred, averaged
accuracy of the associations from 100 data sets are marked for shared, spe-
cific and empty component, along with 1SE. The figure demonstrates the
models ability to accurately discover the component-view associations.
To demonstrate that the model can infer the true associations between
multiple side-data views and components, we perform the first experiment
using synthetic data set. Specifically, the cwKBMF method has been de-
signed to learn the complex relationships patterns, by representing them as
activity profiles of components over the views.
To this end, 100 synthetic data sets Y withNx = 100, Nz = 100 andR = 3
components were generated such that each data set was supplemented with
Px = 10 side-data views (encoded as kernels). The associations between the
Px = 10 side-data views and K = 3 components were encoded such that one
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view is active in all the components (shared), while the rest are equally split
into K+1 sets, where each view is either active in one component (specific)
or not active in any of the components (empty). Here the key assumption
is that given the kernels for Px = 10 side-data views and the output matrix
Y, the model decomposes Y into components while accurately learning the
associations between kernels and components. In addition, 1% values in each
Y were marked as missing data (test set) to measure the predictive accuracy
of the model.
The model is run for each of the 100 data sets to learn the associations.
The component-view weights esx represent the activity of each view x = 1 : Px
in components s = 1 : R. Since the model is encoded with an element-wise
prior it can be effectively thresholded to illustrate component-view activity.
In order to focus on the most important associations for each component,
we consider the associations that are notably strong with respect to the
prior (i.e., z-score (esx) > 0.67) as active. Figure 1 (left) shows the resulting
component-view activities inferred by the model for Px = 10. The figure
demonstrates that the model is able to accurately discover the component-
view activities as inserted in the data (described above), up to a random
permutation of the components.
Next, we measured the accuracy of the model in inferring the component-
view activities as well as in predicting unobserved values in Y over a range
of side-data views Px. The associations were learned and prediction perfor-
mance was evaluated for 100 data sets for each value of Px. Figure 1 (right
panel) demonstrates the accuracy of learning the associations, particularly
the model performs well in discovering the shared, specific as well as empty
components over the range of input views. In addition, Figure 1 (middle
panel), cwKBMF consistently outperforms KBMF in the prediction task as
well, especially when the number of views is large. As expected, the perfor-
mance of the methods deteriorates as the number of views (dimensionality)
increases. However, cwKBMF performs reasonably well over the number of
views applicable to the drug-response prediction data sets in this study.
Cancer Data Sets
We next compare cwKBMF with alternatives on two case studies GDSC and
CTRP, and report their predictive performance in the 5-fold cross validation
procedure (described in Section 3). To evaluate the new model extension and
the benefit of the principled incorporation of prior knowledge, we compare
cwKBMF’s performance to other methods in two scenarios,
1. Genomic Data + Prior Knowledge: The genomic features are divided
into several side-data views based on the prior knowledge about the
12
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Figure 2: Prediction performances (Spearman correlation) averaged over
drugs with a 5 fold cross-validation procedure repeated 10 times. GDSC
data set (left) and CTRP data set (right). Method abbreviation: cwKBMF,
kernelized Bayesian matrix factorization with component-wise MKL; KBMF,
kernelized Bayesian matrix factorization; BMTMKL, Bayesian multi-task
MKL; KPMF, kernelized probabilistic matrix factorization; MT-LR, multi-
task sparse linear regression; Baseline, mean of the training data. The pre-
dictive performance obtained by cwKBMF for both scenarios is found to be
significantly higher than the others (p<0.05; one-sided paired Wilcoxon Sign-
Rank test corrected for multiple testing, supplementary material Tables S3
and S6).
pathways. We represent this scenario with a subscript multi− view in
the results; and
2. Genomic Data (only): The genomic features are used as a single view
and does not benefits from the prior knowledge. We denote this scenario
with a subscript single− view in the results.
Figures 2 show the predictive performances of all the methods on the GDSC
(left) and CTRP (right) data sets. cwKBMF outperforms its competitors
for both scenarios. Even though the differences in performances are rather
small, the predictive performance obtained by cwKBMF for both scenarios
is found to be significantly higher than the others (p<0.05; one-sided paired
Wilcoxon Sign-Rank test corrected for multiple testing, supplementary ma-
terial Table S3) in GDSC data set respectively. Similarly in CTRP data set,
the predictive performance obtained by cwKBMF for both scenarios is also
significantly higher than the others (p<0.05; one-sided paired Wilcoxon Sign-
Rank test, corrected for multiple testing, supplementary material Table S6).
In the GDSC and CTRP data sets, the maximum predictive performance
of cwKBMF is achieved with 10 and 20 components, respectively. However,
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in-case of multiple maxima a practical choice could be to prefer solutions
with smallest-R in the interest of simpler representations. We chose these
components and discuss a detailed comparison of the predictions of cwKBMF
with other methods.
In GDSC data set, cwKBMFsingle-view outperforms Baseline, MT-LRsingle-view
and KPMFsingle-view (p<0.05; one sided paired Wilcoxon Sign-Rank test, for
comparing Spearman correlations). cwKBMFmulti-view outperforms KBMFmulti-view
and Baseline methods (p<0.05; one-sided paired Wilcoxon Sign-Rank test,
supplementary material Figure S1). Although cwKBMFmulti-view performance
is better than BMTMKLmulti-view (averaged Spearman correlations 0.2253 and
0.2167, respectively), the difference is not statistically significant (p=0.11;
one-sided paired Wilcoxon Sign-Rank test).
Similarly, in CTRP data set, cwKBMFsingle-view outperforms Baseline and
MT-LRsingle-view (p<0.05; one-sided paired Wilcoxon Sign-Rank test). Al-
though cwKBMFsingle-view performance is better than KPMFsingle-view (aver-
aged Spearman correlation 0.1776 and 0.1673, respectively), the difference
is not statistically significant (p=0.07, one-sided paired Wilcoxon Sign-Rank
test). cwKBMFmulti-view give better predictions than Baseline, BMTMKLmulti-view
and KBMFmulti-view (p<0.05; one-sided paired Wilcoxon Sign-Rank test, sup-
plementary material Figure S3).
The prediction results generalize previous findings that non-linear models
improve drug response predictions (Costello et al., 2014). Figure 2 clearly
shows that non-linear methods are better than the linear counterpart, for
predicting drug responses in both data sets.
Having established that our model outperforms existing methods in both
single-view and multi-view settings, we next specifically study the advantage
of using prior pathway and target knowledge. To this end, Figure 3 illustrates
the improvement in performance (in % units) relative to Baseline and when
genomic data is supplemented with prior knowledge.
As the first observation, the introduction of genomic data via different
methods outperforms the baseline predictions demonstrating the genomic fea-
tures are response predictive. Secondly, incorporating prior biological knowl-
edge improves the prediction performance systematically over a range of
methods. Third, systematically modelling the associations between pathway-
based genomic profiles and drug response with cwKBMF outperforms the
existing approaches in predicting drug responses. Specifically, in case of the
GDSC data set, using genomic data with cwKBMF improves the prediction
performance by 21% and when the genomic data is supplemented with prior
knowledge the performance is improved by 22%. Similarly, in case of the
CTRP dataset, using genomic data with cwKBMF improves the prediction
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Figure 3: Pathway-based groups of genes (prior biological knowledge) im-
proves predictive performance. Left, GDSC data set and Right, CTRP data
set. The height of the bar (y-axis) denotes the percentage increase in per-
formance relative to Baseline, computed using the Spearman correlations
averaged over drugs. On x-axis, the bars are grouped based on the type of
learning data used, where “ Genomic Data” means that all of the genes are
used as one group and “Genomic Data + Prior Knowledge” means that all of
the genes are used, grouped into several sets based on the pathway knowledge
and lastly “No Genomic Data” implies that only mean of the training drug
response data is used for prediction.
performance by 17% and when the genomic data is supplemented with prior
knowledge the performance is improved by 20%. The findings also suggest
that incorporating the prior knowledge is more beneficial when the number
of samples is smaller (for instance, in the CTRP data set).
Fully Blinded Experimental Validations: Finally, we experiment-ally
validated the drug response predictions of our model using an in-house Acute
Myeloid Leukemia (AML) cell line panel (Malani et al., manuscript in prepa-
ration). The model is learned, analogously to the experiments with public
data sets above, using the available training drug response data. Specifically,
we made drug response predictions for 8 compounds using 6 AML cell lines
of which 83% measurments were not available for initial model training. To
validate the predictions, an independent experiment was carried out in lab-
oratory. The predicted drug responses were found to be correlated with the
independent lab measurements (Spearman correlation 0.44 Figure 4, p<0.05;
compared to the distribution of correlation values obtained via randomiza-
tion; supplementary material Figure S4). This fully-blinded experimental
validation confirms the predictive power of the model, and gives confidence
that in silico predictions are fairly robust and may be used to study the
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Figure 4: Prediction of the drug sensitivity score (DSS; (Yadav et al., 2014))
of 8 compounds in 6 AML cell lines. The y-axis shows the predictions made
by the cwKBMF model and the x-axis the corresponding validations as mea-
sured in the lab. The predictions have a spearman correlation of 0.44, and
the correlation increases to 0.70, if the outlier venetoclax is excluded.
spectrum of therapeutic choices.
Inferring Pathway-Drug Response Associations
The use of prior knowledge not only improves the prediction performance, but
also helps to infer pathway-drug response associations by cwKBMF, being
the first kernelized method making it possible to study such associations. We
next study the pathway-drug response associations in the GDSC dataset.
We selected the model learned with 10 components based on cross-validation
(as discussed in section 4) and show the pathway-drug response associations
in Figure 5. A component can be characterized by the set of pathways that
are active in it and the drugs whose responses they are predictive off, yielding
hypotheses of pathways associated with drug responses. The hypotheses gen-
erated by all the ten components are illustrated in Figure 5, while those from
the first two components are elaborated in detail below. In order to analyse
target-driven effects, the components were sorted based on the consistency
of the drug targets in the components.
Component 1 is characterized by EGFR/ERBB2 inhibitors, lapatinib,
erlotinib, BIBW2992 (afatinib) and gefitinib. On the pathway side, we
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found reactome SHC1 events in EGFR signalling, reactome GRB2 events
in ERBB2 signaling, among the top 10 pathways. It is biologically meaning-
ful that the inhibitors are related to the EGFR signaling, making it possible
to inhibit the pathways activity in cancer using the EGFR inhibitors. It
is also evident that signaling pathways RAS-RAF-MAPK, PI3K/AKT and
JAK/STAT mediate the downstream effect of EGFR autophosphorylation,
thus affecting cellular proliferation, anti-apoptosis, metastasis and tumor in-
vasion (Whirl-Carrillo et al., 2012). We give additional details of component 1
explaining the variation of EFGR responses in supplementary material Figure
S2 (left). Other drugs explained by the component are aicar (target: AMPK
agonist), thapsigargin (target: ATPase, Ca++ transporting, cardiac muscle,
slow twitch 2), OSU-03012 (target: PDK1/PDPK1), GSK-650394 (target:
SGK3), WZ-1-84 (target: BMX) and AZD-0530 (target: SRC, ABL1). The
pathways involved in mediating the downstream signaling may generate novel
hypotheses for the action mechanism of these drugs.
Component 2 is representative of MEK inhibitors RDEA119 (refame-
tinib), PD-0325901, CI-1040 and AZD6244. Interestingly, on the pathway
side, MEK up..v1 up is identified as one of the top pathways (shown in
Figure 5). It is biologically plausible that the drugs are connected to the
up-regulation of MEK pathway, making it possible to inhibit the pathway
activity in cancer using the MEK inhibitors. It is also known that MEK in-
hibition leads to PI3K/AKT activation (Turke et al., 2012), supporting the
identification of the AKT-related pathways in this component. In general,
stimulation of the PI3K/AKT/mTOR cascade enhances growth, survival,
and metabolism of many cancer cells, and therefore PI3K/AKT/mTOR sig-
naling pathway is a promising therapeutic target for cancer therapy. We
give additional details of component 2 explaining the variation of MEK re-
sponses in supplementary material Figure S2 (right). Other drugs explained
by the component are bexarotene (target: Retinioic acid X family agonist),
bicalutamide (target: Androgen receptor ANDR), MG-132 (target: Protea-
some), TGX221 (target: PI3K beta), Salubrinal (target: GADD34-PP1C
phosphatase) and FH535. In particular FH535 primary target is unknown,
however it has been shown to downregulate the activity of Wnt/β-Catenin
signaling pathway (Gedaly et al., 2014; Liu et al., 2014). The presence of
FH535 in this component suggests potential associations between FH535 re-
sponse, MEK and AKT-related pathways, which could be further investi-
gated in the lab to identify novel biomarkers for predicting FH535 responses.
The analysis conclude that pathway-drug response associations provide bi-
ologically meaningful findings. Even though these are well-known cancer-
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Figure 5: Pathway-response associations decomposed into components in the
GDSC data set, visualized as an “eye diagram” showing cwKBMF 10 com-
ponents (circles), connecting pathways (right) and drugs (with their primary
targets in parenthesis; left). The widths of the curves from the components
to pathways and drugs indicate the strength of the corresponding associa-
tions. For each component, 10 drugs and 10 pathways showing the largest
strength are shown. 18
related pathways (serving as proof-of-concept positive controls), the current
clinical challenge is to find the patients in which these pathways are per-
turbed, making it possible to select targeted treatments like MEK inhibitors
individually.
5 Conclusion
We extended the KBMF method with a novel approach of component-wise
MKL. In experiments with two publicly available cancer data sets, the new
method showed improved predictive performance compared to other methods
(including its predecessor KBMF). Additionally, we confirmed the predictive
performance of the method using an in-house AML cell line panel with exper-
imental validation, performed independently in the lab. We also showed that
incorporating prior knowledge in the form of pathways helps to improve the
prediction performance. We also demonstrated the usefulness of component-
wise MKL, combined with prior knowledge for inferring the associations be-
tween pathways and drug responses. This way of analyzing drug responses
with groups of genes (encoded in the form of pathways) may enhance our
understanding of the action mechanism of drugs and can potentially be used
to identify novel predictive biomarkers for designing new therapies in cancer.
In the future, the method could further be extended with strict sparsity as-
sumptions for component-wise MKL, facilitating the discovery of potentially
strong associations between pathways and drug responses.
Acknowledgement
Funding: This work was financially supported by the Academy of Finland
(Finnish Center of Excellence in Computational Inference Research COIN;
grants 295503 and 292337 to MA and SK; grants 272437, 269862, 279163
to TA), and Cancer Society of Finland (TA). We acknowledge the compu-
tational resources provided by Aalto Science-IT project and CSC-IT Center
for Science Ltd.
Availability:
The source code implementing the method is available at http://research.
cs.aalto.fi/pml/software/cwkbmf/.
19
References
Ammad-ud din, M., Georgii, E., Gönen, M., Laitinen, T., Kallioniemi, O., Wennerberg, K., Poso, A., and Kaski,
S. (2014). Integrative and personalized QSAR analysis in cancer by kernelized Bayesian matrix factorization.
J. Chem. Inf. Model., 54(8):2347–2359.
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J.,
Kryukov, G. V., Sonkin, D., et al. (2012). The cancer cell line encyclopedia enables predictive modelling of
anticancer drug sensitivity. Nature, 483(7391):603–607.
Basu, A., Bodycombe, N. E., Cheah, J. H., Price, E. V., Liu, K., Schaefer, G. I., Ebright, R. Y., Stewart, M. L.,
Ito, D., Wang, S., et al. (2013). An interactive resource to identify cancer genetic and lineage dependencies
targeted by small molecules. Cell, 154(5):1151–1161.
Baxter, J. (2000). A model of inductive bias learning. J. Artif. Intell. Res.(JAIR), 12(149-198):3.
Ben-Hur, A. and Noble, W. S. (2005). Kernel methods for predicting protein–protein interactions. Bioinformat-
ics, 21(suppl 1):i38–i46.
Benjamini, Y. and Hochberg, Y. (1995). Controlling the false discovery rate: a practical and powerful approach
to multiple testing. Journal of the Royal Statistical Society. Series B (Methodological), pages 289–300.
Benjamini, Y. and Yekutieli, D. (2001). The control of the false discovery rate in multiple testing under depen-
dency. Annals of statistics, pages 1165–1188.
Chen, B.-J., Litvin, O., Ungar, L., and Pe’er, D. (2015). Context sensitive modeling of cancer drug sensitivity.
PloS one, 10(8):e0133850.
Cichonska, A., Rousu, J., and Aittokallio, T. (2015). Identification of drug candidates and repurposing oppor-
tunities through compound–target interaction networks. Expert opinion on drug discovery, 10:1–13.
Cortés-Ciriano, I., van Westen, G. J., Bouvier, G., Nilges, M., Overington, J. P., Bender, A., and Malliavin,
T. E. (2015). Improved large-scale prediction of growth inhibition patterns using the NCI60 cancer cell line
panel. Bioinformatics, 31:btv529.
Costello, J. C., Heiser, L. M., Georgii, E., Gönen, M., Menden, M. P., Wang, N. J., Bansal, M., Hintsanen, P.,
Khan, S. A., Mpindi, J.-P., et al. (2014). A community effort to assess and improve drug sensitivity prediction
algorithms. Nature biotechnology, 32(12):1202–1212.
Friedman, J., Hastie, T., and Tibshirani, R. (2010). Regularization paths for generalized linear models via
coordinate descent. Journal of statistical software, 33(1):1.
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P.,
Thompson, I. R., Luo, X., Soares, J., Liu, Q., Iorio, F., Surdez, D., Chen, L., Milano, R. J., Bignell, G. R.,
Tam, A. T., Davies, H., Stevenson, J. A., Barthorpe, S., Lutz, S. R., Kogera, F., Lawrence, K., McLaren-
Douglas, A., Mitropoulos, X., Mironenko, T., Thi, H., Richardson, L., Zhou, W., Jewitt, F., Zhang, T.,
O’Brien, P., Boisvert, J. L., Price, S., Hur, W., Yang, W., Deng, X., Butler, A., Choi, H. G., Chang, J. W.,
Baselga, J., Stamenkovic, I., Engelman, J. A., Sharma, S. V., Delattre, O., Saez-Rodriguez, J., Gray, N. S.,
Settleman, J., Futreal, P. A., Haber, D. A., Stratton, M. R., Ramaswamy, S., McDermott, U., and Benes,
C. H. (2012). Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature,
483(7391):570–575.
Gedaly, R., Galuppo, R., Daily, M. F., Shah, M., Maynard, E., Chen, C., Zhang, X., Esser, K. A., Cohen, D. A.,
Evers, B. M., et al. (2014). Targeting the Wnt/β-catenin signaling pathway in liver cancer stem cells and
hepatocellular carcinoma cell lines with fh535. PloS one, 9(6):e99272.
Gönen, M. (2012). Predicting drug–target interactions from chemical and genomic kernels using Bayesian matrix
factorization. Bioinformatics, 28(18):2304–2310.
Gönen, M. and Alpaydın, E. (2011). Multiple kernel learning algorithms. The Journal of Machine Learning
Research, 12:2211–2268.
Gönen, M. and Kaski, S. (2014). Kernelized Bayesian Matrix Factorization. Pattern Analysis and Machine
Intelligence, IEEE Transactions on, 36(10):2047–2060.
20
Gönen, M., Khan, S., and Kaski, S. (2013). Kernelized Bayesian Matrix Factorization. In Proceedings of The
30th International Conference on Machine Learning, pages 864–872.
Jang, I. S., Neto, E. C., Guinney, J., Friend, S. H., and Margolin, A. A. (2014). Systematic assessment of
analytical methods for drug sensitivity prediction from cancer cell line data. In Pacific Symposium on
Biocomputing. Pacific Symposium on Biocomputing, page 63. NIH Public Access.
Liberzon, A., Subramanian, A., Pinchback, R., Thorvaldsdóttir, H., Tamayo, P., and Mesirov, J. P. (2011).
Molecular signatures database (msigdb) 3.0. Bioinformatics, 27(12):1739–1740.
Liu, J., Li, G., Liu, D., and Liu, J. (2014). Fh535 inhibits the proliferation of hepg2 cells via downregulation of
the Wnt/β-catenin signaling pathway. Molecular medicine reports, 9(4):1289–1292.
Menden, M. P., Iorio, F., Garnett, M., McDermott, U., Benes, C., Ballester, P. J., and Saez-Rodriguez, J. (2013).
Machine learning prediction of cancer cell sensitivity to drugs based on genomic and chemical properties. PLoS
One, 8(4):e61318.
Myint, K. Z. and Xie, X.-Q. (2010). Recent advances in fragment-based qsar and multi-dimensional qsar methods.
Int. J. Mol. Sci., 11(10):3846–3866.
Perkins, R., Fang, H., Tong, W., and Welsh, W. J. (2003). Quantitative structure-activity relationship methods:
Perspectives on drug discovery and toxicology. Environ. Toxicol. Chem., 22(8):1666–1679.
Shao, C.-Y., Chen, S.-Z., Su, B.-H., Tseng, Y. J., Esposito, E. X., and Hopfinger, A. J. (2013). Dependence
of qsar models on the selection of trial descriptor sets: A demonstration using nanotoxicity endpoints of
decorated nanotubes. J. Chem. Inf. Model., 53(1):142–158.
Sutherland, J. J., O’Brien, L. A., and Weaver, D. F. (2004). A comparison of methods for modeling quantitative
structure-activity relationships. J. Med. Chem., 47(22):5541–5554.
Turke, A. B., Song, Y., Costa, C., Cook, R., Arteaga, C. L., Asara, J. M., and Engelman, J. A. (2012). MEK
inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. Cancer
research, 72(13):3228–3237.
Whirl-Carrillo, M., McDonagh, E., Hebert, J., Gong, L., Sangkuhl, K., Thorn, C., Altman, R., and Klein, T. E.
(2012). Pharmacogenomics knowledge for personalized medicine. Clinical pharmacology and therapeutics,
92(4):414.
Yadav, B., Pemovska, T., Szwajda, A., Kulesskiy, E., Kontro, M., Karjalainen, R., Majumder, M. M., Malani, D.,
Murumägi, A., Knowles, J., et al. (2014). Quantitative scoring of differential drug sensitivity for individually
optimized anticancer therapies. Scientific reports, 4.
Yamanishi, Y., Pauwels, E., and Kotera, M. (2012). Drug side-effect prediction based on the integration of
chemical and biological spaces. J. Chem. Inf. Model., 52(12):3284–3292.
Yang, W., Soares, J., Greninger, P., Edelman, E. J., Lightfoot, H., Forbes, S., Bindal, N., Beare, D., Smith, J. A.,
Thompson, I. R., et al. (2013). Genomics of drug sensitivity in cancer (GDSC): a resource for therapeutic
biomarker discovery in cancer cells. Nucleic Acids Res., 41(D1):D955–D961.
Zhang, N., Wang, H., Fang, Y., Wang, J., Zheng, X., and Liu, X. S. (2015). Predicting anticancer drug responses
using a dual-layer integrated cell line-drug network model. PLoS Comput Biol, 11(9):e1004498.
Zhou, T., Shan, H., Banerjee, A., and Sapiro, G. (2012). Kernelized probabilistic matrix factorization: Exploiting
graphs and side information. In SDM, volume 12, pages 403–414. SIAM.
21
S1 Supplementary Material
Case Study: GDSC Data Set
Below, we provide supplementary information of the data and results from
the GDSC data set as discussed in the main text sections 3 and 4.
Table S1 shows the names, type and tissue of 124 cancer cell lines and names,
primary targets of 124 drugs used in our study. We obtained these data from
Genomics of Drug Sensitivity in Cancer project Yang et al. (2013), and show
here for the purpose of motivating reproducibility of the results. For defining
compact primary targets, we annotated their names so that they belong to
one class of targets, for instance MEK1/2 were named to MEK. Table S2 list
the 71 pathways used in the case study.
Table S3 shows the statistical significance of the predictive performances of
cwKBMF compared to other methods on the GDSC data set. Figure S1 com-
pares the predictive performance of cwKBMF with other methods on GDSC
data, when learned with 10 components (see details in main text section 4).
Figure S2 shows the variation of drug responses explained by the two com-
ponents of the cwKBMF model. For component 1, the drug response pattern
can be hypothesized in the following manner: the EGFR inhibitors showing a
response to the set of cell lines (at the lower part), inhibit the EGFR activity
which in turn inhibits the activation of the downstream signaling pathways,
whereas the inhibitors showing no response to the cell lines (on the upper
part) fail to inhibit the EGFR activation, resulting the downstream signaling
pathways to be active.
Similarly for component 2, the MEK inhibitors showing response to the set of
cell lines (at the lower part), inhibit the MEK activity„ whereas the inhibitors
showing no response to the cell lines (on the upper part) fail to inhibit the
MEK pathways.
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Cell line Type Tissue Drug Primary Target Annotated Target
1 ES3 bone ewings_sarcoma Erlotinib EGFR EGFR
2 ES5 bone ewings_sarcoma Rapamycin MTOR MTOR
3 EW-11 bone ewings_sarcoma Sunitinib PDGFRA, PDGFRB, KDR, KIT, FLT3 PDGFR
4 NCI-H1395 lung lung_NSCLC_adenocarcinoma PHA-665752 MET MET
5 NCI-H1770 lung lung_NSCLC_not_specified MG-132 Proteasome Proteasome
6 DMS-114 lung lung_small_cell_carcinoma Paclitaxel Microtubules Microtubules
7 NCI-H1092 lung lung_small_cell_carcinoma Cyclopamine SMO SMO
8 NCI-H2141 lung lung_small_cell_carcinoma AZ628 BRAF BRAF
9 NCI-H345 lung lung_small_cell_carcinoma Sorafenib PDGFRA, PDGFRB, KDR, KIT, FLT3 PDGFR
10 NCI-H446 lung lung_small_cell_carcinoma VX-680 Aurora A/B/C, FLT3, ABL1, JAK2, FLT3
11 NCI-H82 lung lung_small_cell_carcinoma Imatinib ABL, KIT, PDGFR PDGFR
12 SK-N-DZ nervous_system neuroblastoma NVP-TAE684 ALK MET, ALK
13 Calu-6 lung lung_NSCLC_adenocarcinoma PF-02341066 MET, ALK MET, ALK
14 LU-65 lung lung_NSCLC_large_cell AZD-0530 SRC, ABL1 SRC
15 SHP-77 lung lung_small_cell_carcinoma S-Trityl-L-cysteine KIF11 KIF11
16 HCC1187 breast breast Z-LLNle-CHO g-secretase g-secretase
17 HCC2157 breast breast Dasatinib ABL, SRC, KIT, PDGFR SRC,ABL
18 HCC2218 breast breast GNF-2 BCR-ABL SRC,ABL
19 BB49-HNC aero_digestive_tract head_and_neck CGP-60474 CDK1/2/5/7/9 CDK
20 CPC-N lung lung_small_cell_carcinoma CGP-082996 CDK4 CDK
21 EC-GI-10 aero_digestive_tract oesophagus A-770041 SRC family SRC,ABL
22 IM-9 blood Myeloma WH-4-023 SRC family, ABL SRC,ABL
23 IST-SL1 lung lung_small_cell_carcinoma WZ-1-84 BMX BMX
24 LB831-BLC urogenital_system Bladder BI-2536 PLK1/2/3 PLK
25 LU-134-A lung lung_small_cell_carcinoma BMS-536924 IGF1R IGF1R
26 MS-1 lung lung_small_cell_carcinoma BMS-509744 ITK ITK
27 MZ7-mel skin melanoma Pyrimethamine Dihydrofolate reductase (DHFR) DHFR
28 NCI-H510A lung lung_small_cell_carcinoma JW-7-52-1 MTOR MTOR
29 SK-MM-2 blood Myeloma A-443654 AKT1/2/3 AKT
30 TE-1 aero_digestive_tract oesophagus GW843682X PLK1 PLK
31 TE-10 aero_digestive_tract oesophagus MS-275 HDAC HDAC
32 HL-60 blood acute_myeloid_leukaemia Parthenolide NFKB1 NFKB1
33 NCI-H226 lung lung_NSCLC_squamous_cell_carcinoma KIN001-135 IKKE IKKE
34 NCI-H23 lung lung_NSCLC_adenocarcinoma TGX221 PI3K beta PI3K
35 SR blood lymphoid_neoplasm_other Bortezomib Proteasome Proteasome
36 UACC-257 skin melanoma XMD8-85 ERK5 (MK07) ERK5
37 TK10 kidney kidney Roscovitine CDKs CDK
38 SF268 nervous_system glioma Salubrinal GADD34-PP1C phosphatase GADD34-PP1C phosphatase
39 KM12 digestive_system large_intestine Lapatinib EGFR, ERBB2 EGFR
40 Becker nervous_system glioma GSK269962A ROCK ROCK
41 697 blood lymphoblastic_leukemia Doxorubicin DNA intercalating DNA
42 COR-L88 lung lung_small_cell_carcinoma Etoposide TOP2 TOP
43 COLO-824 breast breast Gemcitabine DNA replication DNA
44 DG-75 blood Burkitt_lymphoma Mitomycin C DNA crosslinker DNA
45 DJM-1 skin skin_other Vinorelbine Microtubules Microtubules
46 DU-4475 breast breast NSC-87877 SHP1/2 (PTN6/11) SHP1/2 (PTN6/11)
47 EB2 blood Burkitt_lymphoma Bicalutamide Androgen receptor (ANDR) ANDR
48 EB-3 blood Burkitt_lymphoma Midostaurin KIT PDGFR
49 GCIY digestive_system stomach CHIR-99021 GSK3B GSK3B
50 GI-ME-N nervous_system neuroblastoma AP-24534 ABL SRC,ABL
51 GOTO nervous_system neuroblastoma AZD6482 PI3Kb (P3C2B) PI3K
52 GT3TKB digestive_system stomach PF-562271 FAK FAK
53 HEL blood acute_myeloid_leukaemia DMOG Prolyl-4-Hydroxylase Hydroxylase
54 HH blood T_cell_leukemia FTI-277 Farnesyl transferase (FNTA) FNTA
55 HT blood B_cell_lymphoma OSU-03012 PDK1 (PDPK1) PDK1
56 IST-MES1 lung mesothelioma Shikonin unknown unknown
57 JiyoyeP-2003 blood Burkitt_lymphoma AKT inhibitor VIII AKT1/2 AKT
58 JVM-2 blood lymphoid_neoplasm_other Embelin XIAP XIAP
59 KARPAS-299 blood anaplastic_large_cell_lymphoma FH535 unknown unknown
60 KARPAS-422 blood B_cell_lymphoma PAC-1 CASP3 activator CASP3
61 KINGS-1 nervous_system glioma IPA-3 PAK PAK
62 KMOE-2 blood acute_myeloid_leukaemia GSK-650394 SGK3 SGK3
63 KP-N-YN nervous_system neuroblastoma BAY 61-3606 SYK SYK
64 L-428 blood Hodgkin_lymphoma Thapsigargin ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 ATPase
65 L-540 blood Hodgkin_lymphoma Obatoclax Mesylate BCL-2, BCL-XL, MCL-1 BCL
66 LNCaP-Clone-FGC urogenital_system prostate BMS-754807 IGF1R IGF1R
67 LS-123 digestive_system large_intestine OSI-906 IGF1R IGF1R
68 LS-411N digestive_system large_intestine Bexarotene Retinioic acid X family agonist Retinoic
69 LS-513 digestive_system large_intestine Bleomycin DNA damage DNA
70 MHH-PREB-1 blood B_cell_leukemia LFM-A13 BTK BTK
71 ML-2 blood acute_myeloid_leukaemia AUY922 HSP90 HSP90
72 MN-60 blood B_cell_leukemia Bryostatin 1 PRKC PRKC
73 MONO-MAC-6 blood acute_myeloid_leukaemia Pazopanib VEGFR, PDGFRA, PDGFRB, KIT PDGFR
74 MPP-89 lung mesothelioma LAQ824 HDAC HDAC
75 NCI-SNU-5 digestive_system stomach Epothilone B Microtubules Microtubules
76 NCI-SNU-16 digestive_system stomach GSK-1904529A IGF1R IGF1R
77 NH-12 nervous_system neuroblastoma Tipifarnib Farnesyl-transferase (FNTA) FNTA
78 NMC-G1 nervous_system glioma AS601245 JNK JNK
79 no-11 nervous_system glioma AICAR AMPK agonist AMPK
80 NOMO-1 blood acute_myeloid_leukaemia Camptothecin TOP1 TOP
81 NCI-H524 lung lung_small_cell_carcinoma Vinblastine Microtubules Microtubules
82 P30-OHK blood lymphoblastic_leukemia Cisplatin DNA crosslinker DNA
83 P31-FUJ blood acute_myeloid_leukaemia Cytarabine DNA synthesis DNA
84 PF-382 blood lymphoblastic_T_cell_leukaemia Docetaxel Microtubules Microtubules
85 Raji blood Burkitt_lymphoma Methotrexate Dihydrofolate reductase (DHFR) DHFR
86 REH blood B_cell_leukemia ATRA Retinoic acid and retinoid X receptor agonist Retinoic
87 SF126 nervous_system glioma Gefitinib EGFR EGFR
88 SJSA-1 bone bone_other ABT-263 BCL2, BCL-XL, BCL-W BCL
89 SK-NEP-1 kidney kidney Vorinostat HDAC inhibitor Class I, IIa, IIb, IV HDAC
90 SW684 soft_tissue fibrosarcoma Nilotinib ABL SRC,ABL
91 SW872 soft_tissue soft_tissue_other RDEA119 MEK1/2 MEK
92 SW962 urogenital_system urogenital_system_other CI-1040 MEK1/2 MEK
93 TUR blood B_cell_lymphoma Temsirolimus MTOR MTOR
94 U-698-M blood B_cell_leukemia AZD-2281 PARP1/2 PARP
95 WSU-NHL blood lymphoid_neoplasm_other ABT-888 PARP1/2 PARP
96 RCC10RGB kidney kidney Bosutinib SRC, ABL, TEC SRC,ABL
97 KURAMOCHI urogenital_system ovary Lenalidomide TNF alpha TNF
98 Ramos-2G6-4C10 blood Burkitt_lymphoma Axitinib PDGFR, KIT, VEGFR PDGFR
99 CW-2 digestive_system large_intestine CEP-701 FLT3, JAK2, NTRK1, RET FLT3
100 COLO-320-HSR digestive_system large_intestine 17-AAG HSP90 HSP90
101 COLO-684 urogenital_system endometrium VX-702 p38 JNK
102 CA46 blood Burkitt_lymphoma AMG-706 VEGFR, RET, c-KIT, PDGFR PDGFR
103 RL blood B_cell_lymphoma KU-55933 ATM ATM
104 SNU-C1 digestive_system large_intestine BIBW2992 EGFR, ERBB2 EGFR
105 ST486 blood Burkitt_lymphoma GDC-0449 SMO SMO
106 BC-1 blood B_cell_lymphoma PLX4720 BRAF BRAF
107 CAS-1 nervous_system glioma BX-795 TBK1, PDK1, IKK, AURKB/C PDK1
108 MFM-223 breast breast NU-7441 DNAPK DNAPK
109 LS-1034 digestive_system large_intestine BIRB 0796 p38, JNK2 JNK
110 HDLM-2 blood Hodgkin_lymphoma JNK Inhibitor VIII JNK JNK
111 KNS-81-FD nervous_system glioma 681640 WEE1, CHK1 CHK1
112 TE-6 aero_digestive_tract oesophagus Nutlin-3a MDM2 MDM
113 TE-12 aero_digestive_tract oesophagus PD-173074 FGFR1/3 FGFR
114 D-263MG nervous_system glioma ZM-447439 AURKB PDK1
115 D-502MG nervous_system glioma RO-3306 CDK1 CDK
116 EW-3 bone ewings_sarcoma PD-0332991 CDK4/6 CDK
117 EW-1 bone ewings_sarcoma GDC0941 PI3K (class 1) PI3K
118 EW-18 bone ewings_sarcoma PD-0325901 MEK1/2 MEK
119 EW-24 bone ewings_sarcoma SB590885 BRAF BRAF
120 LAN-6 nervous_system neuroblastoma AZD6244 MEK1/2 MEK
121 NB10 nervous_system neuroblastoma BMS-708163 gamma-secretase G-secretase
122 NB6 nervous_system neuroblastoma JNJ-26854165 MDM2 MDM
123 NB5 nervous_system neuroblastoma TW 37 BCL-2, BCL-XL BCL
124 NB14 nervous_system neuroblastoma AG-014699 PARP1, PARP2 PARP
Table S1: Cell lines and drugs used in the GDSC case study.
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Pathway Name Reference
1 BIOCARTA_EGFR_SMRTE_PATHWAY http://www.broadinstitute.org/gsea/msigdb/cards/BIOCARTA_EGFR_SMRTE_PATHWAY
2 PID_VEGF_VEGFR_PATHWAY http://www.broadinstitute.org/gsea/msigdb/cards/PID_VEGF_VEGFR_PATHWAY
3 REACTOME_SIGNALING_BY_EGFR_IN_CANCER http://www.broadinstitute.org/gsea/msigdb/cards/REACTOME_SIGNALING_BY_EGFR_IN_CANCER
4 REACTOME_EGFR_DOWNREGULATION http://www.broadinstitute.org/gsea/msigdb/cards/REACTOME_EGFR_DOWNREGULATION
5 REACTOME_SHC1_EVENTS_IN_EGFR_SIGNALING http://www.broadinstitute.org/gsea/msigdb/cards/REACTOME_SHC1_EVENTS_IN_EGFR_SIGNALING
6 KEGG_MTOR_SIGNALING_PATHWAY http://www.broadinstitute.org/gsea/msigdb/cards/KEGG_MTOR_SIGNALING_PATHWAY
7 BIOCARTA_MTOR_PATHWAY http://www.broadinstitute.org/gsea/msigdb/cards/BIOCARTA_MTOR_PATHWAY
8 BIOCARTA_IGF1MTOR_PATHWAY http://www.broadinstitute.org/gsea/msigdb/cards/BIOCARTA_IGF1MTOR_PATHWAY
9 PID_MTOR_4PATHWAY http://www.broadinstitute.org/gsea/msigdb/cards/PID_MTOR_4PATHWAY
10 REACTOME_ENERGY_DEPENDENT_REGULATION_OF_MTOR_BY_LKB1_AMPK http://www.broadinstitute.org/gsea/msigdb/cards/REACTOME_ENERGY_DEPENDENT_REGULATION_OF_MTOR_BY_LKB1_AMPK
11 PID_KIT_PATHWAY http://www.broadinstitute.org/gsea/msigdb/cards/PID_KIT_PATHWAY
12 REACTOME_REGULATION_OF_KIT_SIGNALING http://www.broadinstitute.org/gsea/msigdb/cards/REACTOME_REGULATION_OF_KIT_SIGNALING
13 BIOCARTA_MET_PATHWAY http://www.broadinstitute.org/gsea/msigdb/cards/BIOCARTA_MET_PATHWAY
14 PID_MET_PATHWAY http://www.broadinstitute.org/gsea/msigdb/cards/PID_MET_PATHWAY
15 BIOCARTA_AKT_PATHWAY http://www.broadinstitute.org/gsea/msigdb/cards/BIOCARTA_AKT_PATHWAY
16 PID_PI3KCI_AKT_PATHWAY http://www.broadinstitute.org/gsea/msigdb/cards/PID_PI3KCI_AKT_PATHWAY
17 REACTOME_NEGATIVE_REGULATION_OF_THE_PI3K_AKT_NETWORK http://www.broadinstitute.org/gsea/msigdb/cards/REACTOME_NEGATIVE_REGULATION_OF_THE_PI3K_AKT_NETWORK
18 REACTOME_PI3K_AKT_ACTIVATION http://www.broadinstitute.org/gsea/msigdb/cards/REACTOME_PI3K_AKT_ACTIVATION
19 REACTOME_AKT_PHOSPHORYLATES_TARGETS_IN_THE_CYTOSOL http://www.broadinstitute.org/gsea/msigdb/cards/REACTOME_AKT_PHOSPHORYLATES_TARGETS_IN_THE_CYTOSOL
20 REACTOME_CD28_DEPENDENT_PI3K_AKT_SIGNALING http://www.broadinstitute.org/gsea/msigdb/cards/REACTOME_CD28_DEPENDENT_PI3K_AKT_SIGNALING
21 REACTOME_PIP3_ACTIVATES_AKT_SIGNALING http://www.broadinstitute.org/gsea/msigdb/cards/REACTOME_PIP3_ACTIVATES_AKT_SIGNALING
22 BIOCARTA_HDAC_PATHWAY http://www.broadinstitute.org/gsea/msigdb/cards/BIOCARTA_HDAC_PATHWAY
23 PID_HDAC_CLASSII_PATHWAY http://www.broadinstitute.org/gsea/msigdb/cards/PID_HDAC_CLASSII_PATHWAY
24 PID_HDAC_CLASSIII_PATHWAY http://www.broadinstitute.org/gsea/msigdb/cards/PID_HDAC_CLASSIII_PATHWAY
25 PID_HDAC_CLASSI_PATHWAY http://www.broadinstitute.org/gsea/msigdb/cards/PID_HDAC_CLASSI_PATHWAY
26 PID_ERBB2_ERBB3_PATHWAY http://www.broadinstitute.org/gsea/msigdb/cards/PID_ERBB2_ERBB3_PATHWAY
27 REACTOME_DOWNREGULATION_OF_ERBB2_ERBB3_SIGNALING http://www.broadinstitute.org/gsea/msigdb/cards/REACTOME_DOWNREGULATION_OF_ERBB2_ERBB3_SIGNALING
28 REACTOME_GRB2_EVENTS_IN_ERBB2_SIGNALING http://www.broadinstitute.org/gsea/msigdb/cards/REACTOME_GRB2_EVENTS_IN_ERBB2_SIGNALING
29 REACTOME_PI3K_EVENTS_IN_ERBB2_SIGNALING http://www.broadinstitute.org/gsea/msigdb/cards/REACTOME_PI3K_EVENTS_IN_ERBB2_SIGNALING
30 ST_JNK_MAPK_PATHWAY http://www.broadinstitute.org/gsea/msigdb/cards/ST_JNK_MAPK_PATHWAY
31 PID_TCR_JNK_PATHWAY http://www.broadinstitute.org/gsea/msigdb/cards/PID_TCR_JNK_PATHWAY
32 REACTOME_JNK_C_JUN_KINASES_PHOSPHORYLATION_AND_ACTIVATION_MEDIATED_BY_ACTIVATED_HUMAN_TAK1 http://www.broadinstitute.org/gsea/msigdb/cards/REACTOME_JNK_C_JUN_KINASES_PHOSPHORYLATION_AND_ACTIVATION_MEDIATED_BY_ACTIVATED_HUMAN_TAK1
33 BIOCARTA_ATM_PATHWAY http://www.broadinstitute.org/gsea/msigdb/cards/BIOCARTA_ATM_PATHWAY
34 PID_ATM_PATHWAY http://www.broadinstitute.org/gsea/msigdb/cards/PID_ATM_PATHWAY
35 REACTOME_IRAK1_RECRUITS_IKK_COMPLEX http://www.broadinstitute.org/gsea/msigdb/cards/REACTOME_IRAK1_RECRUITS_IKK_COMPLEX
36 REACTOME_ACTIVATION_OF_IRF3_IRF7_MEDIATED_BY_TBK1_IKK_EPSILON http://www.broadinstitute.org/gsea/msigdb/cards/REACTOME_ACTIVATION_OF_IRF3_IRF7_MEDIATED_BY_TBK1_IKK_EPSILON
37 REACTOME_IKK_COMPLEX_RECRUITMENT_MEDIATED_BY_RIP1 http://www.broadinstitute.org/gsea/msigdb/cards/REACTOME_IKK_COMPLEX_RECRUITMENT_MEDIATED_BY_RIP1
38 REACTOME_NEGATIVE_REGULATION_OF_FGFR_SIGNALING http://www.broadinstitute.org/gsea/msigdb/cards/REACTOME_NEGATIVE_REGULATION_OF_FGFR_SIGNALING
39 REACTOME_SIGNALING_BY_FGFR_IN_DISEASE http://www.broadinstitute.org/gsea/msigdb/cards/REACTOME_SIGNALING_BY_FGFR_IN_DISEASE
40 REACTOME_SIGNALING_BY_FGFR_MUTANTS http://www.broadinstitute.org/gsea/msigdb/cards/REACTOME_SIGNALING_BY_FGFR_MUTANTS
41 REACTOME_FGFR_LIGAND_BINDING_AND_ACTIVATION http://www.broadinstitute.org/gsea/msigdb/cards/REACTOME_FGFR_LIGAND_BINDING_AND_ACTIVATION
42 PID_IL2_PI3K_PATHWAY http://www.broadinstitute.org/gsea/msigdb/cards/PID_IL2_PI3K_PATHWAY
43 PID_PI3K_PLC_TRK_PATHWAY http://www.broadinstitute.org/gsea/msigdb/cards/PID_PI3K_PLC_TRK_PATHWAY
44 REACTOME_PI3K_EVENTS_IN_ERBB4_SIGNALING http://www.broadinstitute.org/gsea/msigdb/cards/REACTOME_PI3K_EVENTS_IN_ERBB4_SIGNALING
45 REACTOME_PI3K_CASCADE http://www.broadinstitute.org/gsea/msigdb/cards/REACTOME_PI3K_CASCADE
46 EGFR_UP.V1_DN http://www.broadinstitute.org/gsea/msigdb/cards/EGFR_UP.V1_DN
47 EGFR_UP.V1_UP http://www.broadinstitute.org/gsea/msigdb/cards/EGFR_UP.V1_UP
48 AKT_UP_MTOR_DN.V1_DN http://www.broadinstitute.org/gsea/msigdb/cards/AKT_UP_MTOR_DN.V1_DN
49 AKT_UP_MTOR_DN.V1_UP http://www.broadinstitute.org/gsea/msigdb/cards/AKT_UP_MTOR_DN.V1_UP
50 MTOR_UP.V1_DN http://www.broadinstitute.org/gsea/msigdb/cards/MTOR_UP.V1_DN
51 MTOR_UP.V1_UP http://www.broadinstitute.org/gsea/msigdb/cards/MTOR_UP.V1_UP
52 MTOR_UP.N4.V1_DN http://www.broadinstitute.org/gsea/msigdb/cards/MTOR_UP.N4.V1_DN
53 MTOR_UP.N4.V1_UP http://www.broadinstitute.org/gsea/msigdb/cards/MTOR_UP.N4.V1_UP
54 JAK2_DN.V1_DN http://www.broadinstitute.org/gsea/msigdb/cards/JAK2_DN.V1_DN
55 JAK2_DN.V1_UP http://www.broadinstitute.org/gsea/msigdb/cards/JAK2_DN.V1_UP
56 ALK_DN.V1_DN http://www.broadinstitute.org/gsea/msigdb/cards/ALK_DN.V1_DN
57 ALK_DN.V1_UP http://www.broadinstitute.org/gsea/msigdb/cards/ALK_DN.V1_UP
58 SRC_UP.V1_DN http://www.broadinstitute.org/gsea/msigdb/cards/SRC_UP.V1_DN
59 SRC_UP.V1_UP http://www.broadinstitute.org/gsea/msigdb/cards/SRC_UP.V1_UP
60 AKT_UP.V1_DN http://www.broadinstitute.org/gsea/msigdb/cards/AKT_UP.V1_DN
61 AKT_UP.V1_UP http://www.broadinstitute.org/gsea/msigdb/cards/AKT_UP.V1_UP
62 JNK_DN.V1_DN http://www.broadinstitute.org/gsea/msigdb/cards/JNK_DN.V1_DN
63 JNK_DN.V1_UP http://www.broadinstitute.org/gsea/msigdb/cards/JNK_DN.V1_UP
64 MEK_UP.V1_DN http://www.broadinstitute.org/gsea/msigdb/cards/MEK_UP.V1_DN
65 MEK_UP.V1_UP http://www.broadinstitute.org/gsea/msigdb/cards/MEK_UP.V1_UP
66 ATM_DN.V1_DN http://www.broadinstitute.org/gsea/msigdb/cards/ATM_DN.V1_DN
67 ATM_DN.V1_UP http://www.broadinstitute.org/gsea/msigdb/cards/ATM_DN.V1_UP
68 TBK1.DF_DN http://www.broadinstitute.org/gsea/msigdb/cards/TBK1.DF_DN
69 TBK1.DF_UP http://www.broadinstitute.org/gsea/msigdb/cards/TBK1.DF_UP
70 TBK1.DN.48HRS_DN http://www.broadinstitute.org/gsea/msigdb/cards/TBK1.DN.48HRS_DN
71 TBK1.DN.48HRS_UP http://www.broadinstitute.org/gsea/msigdb/cards/TBK1.DN.48HRS_UP
Table S2: List of pathways used in the GDSC case study. Some of the names
are modified so that they can fit into the eye diagram (main text Figure
5). For example, reactome SHC1 events in EGFR signaling is modified as
re:SHC1 event events in EGFR signaling.
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Figure S1: Comparison of cwKBMF with other methods on GDSC data.
Spearman rank correlation between the predictions and the response data,
for each drug are calculated for each method. The correlations from each
method (x-axis) are compared to those from cwKBMF (y-axis) with compo-
nents 10. Each dot represents cross validated prediction performance for a
drug response averaged over 10 random rounds of 5 fold cross-validation pro-
cedure. The subscript in method’s name denotes the format of learning data
used by the methods; single-view means that the method is learned using
one view (i.e, one group containing all the genomic features), while multi-
view means that the method is learned using multiple views (i.e., genomic
features are grouped into many views based on the prior knowledge about
the pathways). Method abbreviation: cwKBMF, kernelized Bayesian matrix
factorization with component-wise MKL; KBMF, kernelized Bayesian ma-
trix factorization; BMTMKL, Bayesian multi-task MKL; KPMF, kernelized
probabilistic matrix factorization; MT-LR, multi-task sparse linear regres-
sion; Baseline, mean of the training data. P-values show the statistical sig-
nificance of the improvements of cwKBMF’s predictions compared to other
methods computed with one-sided paired Wilcoxon Sign-Rank test.
.
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Figure S2: Variation in drug responses explained by cwKBMF components.
Component 1 explains EGFR inhibitors and component 2 models MEK in-
hibitors. The heat map (in center) shows the actual drug responses of the
inhibitors (x-axis), on top 10 cancer cell lines (y.axis). Bar plots on x- and
y- axis, indicate the weights of the inhibitors and cell lines learned by the
cwKBMF method, respectively. FH535 (with unknown primary target) ex-
plained by component 2, shows variations in responses similar to MEK in-
hibitors.
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Table S3: Statistical significance of the predictive performances on the GDSC
data set. P-values from one-sided paired Wilcoxon Sign-Rank test corre-
sponding to the curves shown in Figure 2 (in the main text), corrected for
multiple testing using Benjamini, Hochberg, and Yekutieli’s method Ben-
jamini and Hochberg (1995),Benjamini and Yekutieli (2001).
Methods cwKBMFsingle−view cwKBMFmulti−view
cwKBMFsingle−view – 1.369× 10−6
KBMFmulti−view – 1.369× 10−6
BMTMKLmulti−view – 2.922× 10−2
KPMFsingle−view 1.369× 10−6 1.369× 10−6
MT-LRsingle−view 2.017× 10−4 2.790× 10−5
Baseline 1.369× 10−6 1.369× 10−6
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Case Study: CTRP Data Set
Below, we provides supplementary information of the data and results from
the CTRP data set as discussed in the main text section 3 and 4.
Table S4 shows the names, types and tissues of 66 cancer cell lines and names,
primary targets of 63 drugs used in our study. We obtained these data from
Cancer Therapeutic Response Portal Basu et al. (2013), and show here for
the purpose of motivating reproducibility of the results. Table S5 list the 25
pathways used in the case study.
Table S6 shows the statistical significance of the predictive performances of
cwKBMF compared to other methods on the GDSC data set. Figure S3
compares the predictive performance of cwKBMF with other methods on
CTRP data, when learned with 20 components.
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Cell line Type Tissue Drug Primary Target
1 A2780 OVARY etoposide TOP2A;TOP2B
2 A375 SKIN oligomycin A ATP5L2
3 AMO1 HEMATOPOIETIC_AND_LYMPHOID_TISSUE PLASMA_CELL_MYELOMA chaetocin SUV39H1
4 BL70 HEMATOPOIETIC_AND_LYMPHOID_TISSUE tubastatin A HDAC6
5 CAL12T LUNG NON_SMALL_CELL_CARCINOMA avrainvillamide NPM1
6 COLO320 LARGE_INTESTINE TG-101348 JAK2
7 COLO678 LARGE_INTESTINE SCH-79797 F2R
8 CORL23 LUNG LARGE_CELL_CARCINOMA HLI 373 MDM2
9 COV318 OVARY indisulam CA9
10 EFO27 OVARY Compound 10b MAP3K8
11 GAMG CENTRAL_NERVOUS_SYSTEM BMS-536924 IGF1R;INSR
12 HCC15 LUNG SQUAMOUS_CELL_CARCINOMA Compound 12 NOS2
13 HCC2935 LUNG NON_SMALL_CELL_CARCINOMA JZL-184 MGLL
14 HCC4006 LUNG ADENOCARCINOMA cerulenin FASN;HMGCS1
15 HCC827 LUNG ADENOCARCINOMA pemetrexed TS;DHFR;GART
16 HCT116 LARGE_INTESTINE serdemetan MDM2
17 HEC151 ENDOMETRIUM tipifarnib-P1 FNTA
18 HEC59 ENDOMETRIUM ATRA RARA;RARB;RARG
19 HEPG2 LIVER SNX-2112 HSP90AA1;HSP90B1
20 HS852T SKIN BRD4770 EHMT2
21 HT1080 SOFT_TISSUE NSC632839 USP5;USP13
22 HT29 LARGE_INTESTINE WT-161 HDAC6
23 IGROV1 OVARY losartan AGTR2
24 JHH6 LIVER vorinostat HDAC1;HDAC2;HDAC3;HDAC6;HDAC8
25 JHOS4 OVARY batimastat MMP1;MMP2;MMP3;MMP7;MMP9
26 JHUEM2 ENDOMETRIUM PF-750 FAAH
27 KLE ENDOMETRIUM 2-bromopyruvate HK2
28 KMS11 HEMATOPOIETIC_AND_LYMPHOID_TISSUE PLASMA_CELL_MYELOMA AC55649 RARB
29 LN229 CENTRAL_NERVOUS_SYSTEM necrostatin-1 RIPK1
30 LP1 HEMATOPOIETIC_AND_LYMPHOID_TISSUE PLASMA_CELL_MYELOMA PX-12 TXN
31 LS123 LARGE_INTESTINE nimodipine CACNA1C;CACNA1D;CACNA1S;CACNA1F
32 MCF7 BREAST lovastatin acid HMGCR
33 MKN74 STOMACH GW-405833 CB2
34 NCIH1694 LUNG SMALL_CELL_CARCINOMA minoxidil KCNJ8;KCNJ11
35 NCIH1915 LUNG LARGE_CELL_CARCINOMA PRIMA-1 TP53
36 NCIH2023 LUNG ADENOCARCINOMA CR-1-31B EIF4A2;EIF4E;EIF4G1
37 NCIH2030 LUNG NON_SMALL_CELL_CARCINOMA CHEMBL399379 ACLY
38 NCIH2122 LUNG ADENOCARCINOMA sildenafil PDE5A
39 NCIH2172 LUNG NON_SMALL_CELL_CARCINOMA selumetinib MAP2K1;MAP2K2
40 NCIH2286 LUNG SMALL_CELL_CARCINOMA TGX-115 PIK3CB;PIK3CD
41 NCIH3255 LUNG ADENOCARCINOMA 10-DEBC AKT
42 NCIH441 LUNG ADENOCARCINOMA BML-259 CDK5;CDK2
43 NCIH460 LUNG LARGE_CELL_CARCINOMA PF-04217903 MET
44 OCILY10 HEMATOPOIETIC_AND_LYMPHOID_TISSUE DIFFUSE_LARGE_B_CELL_LYMPHOMA purmorphamine SMO
45 OV90 OVARY RG-108 DNMT1
46 OVCAR4 OVARY tosedostat LAP3;NPEPPS;ANPEP
47 OVCAR8 OVARY eflornithine ODC1
48 OVMANA OVARY LY-2365109 SLC6A9
49 PATU8902 PANCREAS ML090 NOX1
50 PC3 PROSTATE bovinocidin SDHA;SDHB;SDHC;SDHD
51 RKN SOFT_TISSUE irosustat STS
52 RKO LARGE_INTESTINE Compound 2 BCAT1
53 SCC9 UPPER_AERODIGESTIVE_TRACT importazole KPNB1
54 SKLU1 LUNG ADENOCARCINOMA YK 4-279 DHX9;ERG;ETV1
55 SKMEL5 SKIN AG14361 PARP1
56 SNGM ENDOMETRIUM narciclasine RHOA
57 SNU398 LIVER 3-aminobenzamide PARP1
58 SNU449 LIVER B02 RAD51
59 SQ1 LUNG SQUAMOUS_CELL_CARCINOMA PJ 34 PARP1
60 SUDHL4 HEMATOPOIETIC_AND_LYMPHOID_TISSUE DIFFUSE_LARGE_B_CELL_LYMPHOMA BRD8899 STK33
61 SW480 LARGE_INTESTINE MK-2206 AKT
62 SW620 LARGE_INTESTINE MLN2238 PSMB5
63 T3M10 LUNG LARGE_CELL_CARCINOMA CAY10618 NAMPT
64 TYKNU OVARY NA NA
65 U2OS BONE NA NA
66 U937 HEMATOPOIETIC_AND_LYMPHOID_TISSUE DIFFUSE_LARGE_B_CELL_LYMPHOMA NA NA
Table S4: Cell lines and drugs used in the CTRP case study.
Pathway Name Reference
1 BIOCARTA_AKT_PATHWAY http://www.broadinstitute.org/gsea/msigdb/cards/BIOCARTA_AKT_PATHWAY
2 PID_PI3KCI_AKT_PATHWAY http://www.broadinstitute.org/gsea/msigdb/cards/PID_PI3KCI_AKT_PATHWAY
3 REACTOME_NEGATIVE_REGULATION_OF_THE_PI3K_AKT_NETWORK http://www.broadinstitute.org/gsea/msigdb/cards/REACTOME_NEGATIVE_REGULATION_OF_THE_PI3K_AKT_NETWORK
4 REACTOME_PI3K_AKT_ACTIVATION http://www.broadinstitute.org/gsea/msigdb/cards/REACTOME_PI3K_AKT_ACTIVATION
5 REACTOME_AKT_PHOSPHORYLATES_TARGETS_IN_THE_CYTOSOL http://www.broadinstitute.org/gsea/msigdb/cards/REACTOME_AKT_PHOSPHORYLATES_TARGETS_IN_THE_CYTOSOL
6 REACTOME_CD28_DEPENDENT_PI3K_AKT_SIGNALING http://www.broadinstitute.org/gsea/msigdb/cards/REACTOME_CD28_DEPENDENT_PI3K_AKT_SIGNALING
7 REACTOME_PIP3_ACTIVATES_AKT_SIGNALING http://www.broadinstitute.org/gsea/msigdb/cards/REACTOME_PIP3_ACTIVATES_AKT_SIGNALING
8 BIOCARTA_MET_PATHWAY http://www.broadinstitute.org/gsea/msigdb/cards/BIOCARTA_MET_PATHWAY
9 PID_MET_PATHWAY http://www.broadinstitute.org/gsea/msigdb/cards/PID_MET_PATHWAY
10 PID_RHOA_PATHWAY http://www.broadinstitute.org/gsea/msigdb/cards/PID_RHOA_PATHWAY
11 PID_RHOA_REG_PATHWAY http://www.broadinstitute.org/gsea/msigdb/cards/PID_RHOA_REG_PATHWAY
12 JAK2_DN.V1_DN http://www.broadinstitute.org/gsea/msigdb/cards/JAK2_DN.V1_DN
13 JAK2_DN.V1_UP http://www.broadinstitute.org/gsea/msigdb/cards/JAK2_DN.V1_UP
14 EIF4E_DN http://www.broadinstitute.org/gsea/msigdb/cards/EIF4E_DN
15 EIF4E_UP http://www.broadinstitute.org/gsea/msigdb/cards/EIF4E_UP
16 AKT_UP_MTOR_DN.V1_DN http://www.broadinstitute.org/gsea/msigdb/cards/AKT_UP_MTOR_DN.V1_DN
17 AKT_UP_MTOR_DN.V1_UP http://www.broadinstitute.org/gsea/msigdb/cards/AKT_UP_MTOR_DN.V1_UP
18 AKT_UP.V1_DN http://www.broadinstitute.org/gsea/msigdb/cards/AKT_UP.V1_DN
19 AKT_UP.V1_UP http://www.broadinstitute.org/gsea/msigdb/cards/AKT_UP.V1_UP
20 STK33_DN http://www.broadinstitute.org/gsea/msigdb/cards/STK33_DN
21 STK33_NOMO_DN http://www.broadinstitute.org/gsea/msigdb/cards/STK33_NOMO_DN
22 STK33_NOMO_UP http://www.broadinstitute.org/gsea/msigdb/cards/STK33_NOMO_UP
23 STK33_SKM_DN http://www.broadinstitute.org/gsea/msigdb/cards/STK33_SKM_DN
24 STK33_SKM_UP http://www.broadinstitute.org/gsea/msigdb/cards/STK33_SKM_UP
25 STK33_UP http://www.broadinstitute.org/gsea/msigdb/cards/STK33_UP
Table S5: List of pathways used in the CTRP case study
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Table S6: Statistical significance of the predictive performances on the CTRP
data set. P-values from one-sided paired Wilcoxon Sign-Rank test corre-
sponding to the curves shown in Figure 2 in the main text, corrected for
multiple testing using Benjamini, Hochberg, and Yekutieli’s method Ben-
jamini and Hochberg (1995),Benjamini and Yekutieli (2001).
Methods cwKBMFsingle−view cwKBMFmulti−view
cwKBMFsingle−view – 3.662× 10−4
KBMFmulti−view – 1.464× 10−3
BMTMKLmulti−view – 1.708× 10−3
KPMFsingle−view 3.662× 10−4 3.662× 10−4
MT-LRsingle−view 7.324× 10−4 3.662× 10−4
Baseline 3.662× 10−4 3.662× 10−4
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Figure S3: Comparison of cwKBMF with other methods on CTRP data set.
Spearman rank correlation between the predictions and the response data,
for each drug are calculated for each method. The correlations from each
method (x-axis) are compared to those from cwKBMF (y-axis) with compo-
nents 10. Each dot represents cross validated prediction performance for a
drug response averaged over 10 random rounds of 5 fold cross-validation pro-
cedure. The subscript in method’s name denotes the format of learning data
used by the methods; single-view means that the method is learned using
one view (i.e, one group containing all the genomic features), while multi-
view means that the method is learned using multiple views (i.e., genomic
features are grouped into many views based on the prior knowledge about
the pathways). Method abbreviation: cwKBMF, kernelized Bayesian matrix
factorization with component-wise MKL; KBMF, kernelized Bayesian ma-
trix factorization; BMTMKL, Bayesian multi-task MKL; KPMF, kernelized
probabilistic matrix factorization; MT-LR, multi-task sparse linear regres-
sion; Baseline, mean of the training data. P-values show the statistical sig-
nificance of the improvements of cwKBMF’s predictions compared to other
methods computed with one-sided paired Wilcoxon Sign-Rank test.
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Figure S4: Statistical significance of in silico predictions obtained via ran-
domizations test with 10000 random permutations of the drug responses.
Spearman correlation = 0.44 found to be significant with p = 0.0027, than
random distribution.
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